Dr. Ana Fidantsef, of the TCS Licensing team, collaborated with CSL in promoting the 2022 Research Acceleration Initiative across UConn and identifying faculties whose research aligned with CSL. CSL Ltd is a leading global biotech company operating in over 35 countries, with headquarters in Australia. CSL develops and delivers innovative biotherapies to help people living with life-threatening medical conditions. CSL’s Research Acceleration Initiative aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organizations. These partnerships provide funding and access to industry experts for scientists working on novel therapeutic strategies. Successful applicants will receive up to $200k p.a. for up to 2 years (max $400k funding).

The 2022 Research Acceleration Initiative was launched in December, 2021 with a focus on innovative research projects that address unmet medical needs and that are aligned with CSL’s Therapeutic Areas and scientific Platform.  A total of 6 applications were submitted by UConn’s faculty through TCS by the close of deadline.

Other opportunities like this can be found on TCS’s Innovation Funding Opportunities webpage.

Author: Dr. Amit Kumar, Senior Director of Licensing